Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 364.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -41.00K | -393.00K | -377.00K | -1.66M | -1.66M | -11.00K |
EBITDA | -156.79M | -129.08M | -104.58M | -106.63M | -69.43M | -21.52M |
Net Income | -142.29M | -129.47M | -96.66M | -104.79M | -70.89M | -22.76M |
Balance Sheet | ||||||
Total Assets | 382.00M | 450.98M | 276.94M | 215.65M | 295.94M | 342.72M |
Cash, Cash Equivalents and Short-Term Investments | 361.91M | 434.09M | 261.81M | 204.42M | 287.25M | 338.55M |
Total Debt | 1.75M | 1.43M | 2.42M | 2.56M | 3.29M | 0.00 |
Total Liabilities | 36.77M | 42.02M | 23.05M | 18.10M | 11.38M | 4.58M |
Stockholders Equity | 345.24M | 408.96M | 253.90M | 197.55M | 284.57M | 338.14M |
Cash Flow | ||||||
Free Cash Flow | -127.00M | -104.51M | -83.73M | -82.43M | -52.27M | -19.92M |
Operating Cash Flow | -127.16M | -104.35M | -83.73M | -82.06M | -50.69M | -19.87M |
Investing Cash Flow | -79.35M | -93.53M | -4.85M | 91.48M | -275.44M | -56.00K |
Financing Cash Flow | 242.10M | 268.82M | 133.41M | 476.00K | 1.39M | 358.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $796.56M | ― | -51.86% | ― | -37.09% | 58.96% | |
54 Neutral | $539.48M | ― | -32.78% | ― | -13.37% | -1025.90% | |
52 Neutral | $296.44M | 13.99 | 9.81% | ― | 2990.57% | ― | |
51 Neutral | $7.84B | -0.18 | -41.53% | 2.28% | 22.72% | -1.87% | |
46 Neutral | $374.74M | ― | -49.72% | ― | ― | 6.82% | |
43 Neutral | $527.17M | ― | -85.18% | ― | -100.00% | 11.89% | |
41 Neutral | ― | ― | -32.07% | 98.22% |
On March 5, 2025, Olema Pharmaceuticals announced the availability of a presentation for investors, highlighting their strategic priorities and clinical pipeline advancements. The company is actively accruing patients for pivotal Phase 3 trials of palazestrant, aiming for a potential commercial launch in 2027, and has announced a new collaboration with Novartis. These developments could significantly impact Olema’s market positioning and offer promising treatment options for breast cancer.